Haisco Strikes $1.5 Billion NewCo Deal with Sentivera for Type 2 Inflammation Asset
Chinese drugmaker Haisco Pharmaceutical Group has struck another billion-dollar cross-border transaction, licensing ex-Greater China rights to a preclinical immunology asset to newly formed U.S. biotech Sentivera in a deal potentially worth more than…
Haisco’s class 1 small-molecule PNH drug has been approved for marketing in China
Today (July 23), the National Medical Products Administration (NMPA) of China announced that it has approved the marketing of Haisco Pharmaceutical‘s Class 1 innovative drug, Succinate Spocoman tablets (HSK39297), through the priority review and…